What Longeveron does

Longeveron Inc. (NASDAQ: LGVN) is a clinical-stage biotechnology company founded in 2014 and headquartered in Miami, Florida, that develops allogeneic mesenchymal stem cell (MSC) therapies for rare pediatric and aging-related conditions. Its lead and only clinical candidate, Lomecel-B (laromestrocel), is a living-cell product manufactured from bone-marrow-derived MSCs of young healthy adult donors, culture-expanded into billions of cells and cryopreserved in single-dose vials (e.g., 50 million cells per dose). The company is evaluating this single product across four distinct indications: Hypoplastic Left Heart Syndrome (HLHS), Pediatric Dilated Cardiomyopathy (PDCM), Alzheimer's disease, and Aging-related Frailty, pursuing a "pipeline in a product" strategy. The platform is supported by 33 issued global patents, proprietary potency assay methodologies, and five FDA designations across programs.

The company is pre-revenue and generates no material product sales; it finances operations through dilutive equity raises. Since 2023 it has executed multiple registered direct offerings and private placements totaling approximately $51 million, most recently a $30 million private placement in March 2026 led by Coastlands Capital with Janus Henderson Investors, Logos Capital, and Kalehua Capital, extending cash runway into Q4 2026. Management has explicitly repositioned toward an asset-light operating model targeting licensing and co-development partnerships across all four indications, presenting at BIO 2026, JPM Healthcare Week, and the CVCT Forum in pursuit of strategic partners. Material value catalysts include the Q3 2026 topline ELPIS II Phase 2b readout in HLHS, a potential Rare Pediatric Disease Priority Review Voucher (recently reauthorized through 2029) worth an estimated $150–200 million on BLA approval, and EMA SME status granted in June 2026 to support European marketing authorization.

Longeveron's competitive position rests on a combination of regulatory designations (Orphan Drug, Fast Track, Rare Pediatric Disease, RMAT, EMA SME), peer-reviewed clinical publications in Nature Medicine and Cell Stem Cell, and scientific leadership anchored by co-founder Dr. Joshua Hare. The company faces a near-term regulatory inflection: a March 2026 FDA Type C meeting concluded that the current primary endpoint of right ventricle ejection fraction in the ELPIS II trial is insufficient to demonstrate efficacy and the agency will no longer refer to the trial as pivotal. Leadership has undergone significant turnover, with Stephen H. Willard appointed permanent CEO in February 2026 following interim CEO Than Powell and the departure of Wa'el Hashad in September 2025, while Dr. Hare remains Executive Chairman and CSO.

Name

Longeveron

Legal name

Longeveron Inc.

Website

https://longeveron.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Longeveron (NASDAQ: LGVN) is a clinical-stage biotechnology company developing a single allogeneic mesenchymal stem cell therapy, Lomecel-B (laromestrocel), evaluated across four indications including Hypoplastic Left Heart Syndrome, Alzheimer's disease, Pediatric Dilated Cardiomyopathy, and aging-related frailty, and is repositioning toward an asset-light licensing model.

Ownership category

akta.pro rank

Product category

Cell Therapy / Regenerative Medicine Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH)

Keywords

• Allogeneic cell therapy
• Mesenchymal stem cells
• Regenerative medicine
• Biopharmaceutical development
• Rare disease therapeutics

Headquarters

HQ city

Miami

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Licensing and Partnership Agreements: Longeveron is pursuing strategic licensing partnerships for its stem cell therapy programs across multiple indications. Upon successful clinical trials and regulatory approval, the company would generate revenue through licensing deals, co-development partnerships, and potential product sales.
2. Priority Review Voucher: Upon BLA approval for Hypoplastic Left Heart Syndrome, Longeveron may be eligible to receive a Rare Pediatric Disease Priority Review Voucher, which can be sold for $150-200 million each.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Longeveron is a clinical-stage biotechnology company developing Lomecel-B (laromestrocel), a proprietary allogeneic mesenchymal stem cell (MSC) therapy isolated from bone marrow of healthy young adult donors, culture-expanded into billions of cells and frozen in doses (e.g., 50 million cells). The therapy is being evaluated across four indications: Hypoplastic Left Heart Syndrome (HLHS), Pediatric Dilated Cardiomyopathy (PDCM), Alzheimer's disease, and Aging-related Frailty, with the company pursuing a licensing/partnership-based commercialization model.

Product overview

Longeveron is a clinical-stage biotechnology company developing a single unified therapeutic product, Lomecel-B (laromestrocel), which is a proprietary allogeneic mesenchymal stem cell therapy. The product is being evaluated across four distinct indications: Hypoplastic Left Heart Syndrome (HLHS), Pediatric Dilated Cardiomyopathy (PDCM), Alzheimer's disease, and Aging-related Frailty. The company's development strategy positions laromestrocel as a 'pipeline in a product' approach, leveraging the same cellular therapy platform across multiple rare pediatric and aging-related conditions. The company operates with five FDA designations supporting various programs.

Differentiator

Problem solved

Functional benefit

Brands

• Lomecel-B: Proprietary allogeneic mesenchymal stem cell therapy (laromestrocel) being evaluated in multiple indications including HLHS, PDCM, Alzheimer's disease, and Age-Related Frailty.

Products and services

• Lomecel-B (laromestrocel) A proprietary, scalable, allogeneic cellular therapy comprised of mesenchymal stem cells (MSCs) isolated from the bone marrow of healthy young adult donors. Laromestrocel is being evaluated across multiple indications including Hypoplastic Left Heart Syndrome (HLHS), Pediatric Dilated Cardiomyopathy (PDCM), Alzheimer's disease, and Aging-related Frailty. The cells are culture-expanded into billions, harvested into doses (e.g., 50 million cells), and frozen for future administration to patients.
• ELPIS II (Phase 2b HLHS Clinical Trial Program) Pivotal Phase 2b clinical trial program evaluating laromestrocel as a potential adjunct therapy for Hypoplastic Left Heart Syndrome (HLHS) in pediatric patients. Trial enrolled 40 patients at 12 leading U.S. pediatric cardiac centers in collaboration with the National Heart, Lung, and Blood Institute. Top-line data anticipated in Q3 2026.
• CLEAR MIND (Phase 2a Alzheimer's Clinical Trial Program) Phase 2a randomized controlled clinical trial evaluating laromestrocel in mild Alzheimer's disease. Phase 2a results were published in Nature Medicine in March 2025, and additional data analysis was accepted for poster presentation at AAIC 2026.
• Pediatric Dilated Cardiomyopathy (PDCM) Development Program Development program for laromestrocel targeting Pediatric Dilated Cardiomyopathy, a rare progressive heart disease affecting approximately 100,000 children worldwide with 40% mortality within two years of diagnosis. IND approved in 2025, with FDA confirming a single Phase 2b/3 study is required.

Quantifiable outcome

• 63.4-meter improvement in 6-minute walk test at 9 months for age-related frailty patients (p=0.0077)
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered supporting and core.

• StartUp HealthsupportingStrategic or Co-development Partner · 1 December 2025Selected as a StartUp Health Alzheimer's Disease Moonshot Company to participate in StartUp Health Apollo House during JPM Healthcare Week 2026, hosting meetings with investors and partners.
• National Heart, Lung, and Blood Institute (NHLBI)coreStrategic or Co-development PartnerClinical collaboration through NIH grants for the ELPIS II Phase 2b trial. The trial enrolled 40 pediatric patients at 12 leading pediatric cardiac centers across the United States in collaboration with NHLBI.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Mesoblast: Commercial-stage developer of allogeneic mesenchymal stem cell therapies (remestemcel-L) for inflammatory and cardiac conditions. Most direct peer to Longeveron in MSC platform, though Mesoblast is further along commercially with FDA-approved products.
• Capricor Therapeutics: Clinical-stage biotech developing cell therapies (CAP-1002, cardiosphere-derived cells) for Duchenne muscular dystrophy and cardiac indications. Comparable stage, size, and cardiac/rare disease focus to Longeveron.
• Pluristem Therapeutics: Developer of placenta-derived allogeneic cell therapies (PLX cells) for multiple indications including muscle injury and hematopoietic recovery. Comparable allogeneic platform model and indication breadth to Longeveron's pipeline approach.
• BrainStorm Cell Therapeutics: Clinical-stage developer of autologous MSC-based therapies (NurOwn) for neurodegenerative diseases including ALS and MS. Direct peer in MSC platform and overlapping neurological indication space (Alzheimer's adjacent).
• Athersys / Healios K.K. Developer of MultiStem allogeneic cell therapy platform for stroke, ARDS, and acute inflammatory conditions. Comparable allogeneic platform architecture and clinical-stage status to Longeveron's MSC approach.
• Lineage Cell Therapeutics: Clinical-stage developer of allogeneic cell therapies for CNS, oncology, and rare diseases with pipeline-in-a-product strategy similar to Longeveron's approach. Comparable size and asset-light partnership orientation.
• Celularity Inc. Clinical-stage developer of placenta-derived allogeneic cell therapies (PDA-002, NK cells) with focus on aging-related conditions and cancer. Highly comparable allogeneic platform and aging-frailty indication overlap with Longeveron.
• BioCardia, Inc. Clinical-stage developer of cell-based therapies for cardiac indications (CardiAMP, CardiALLO) with focus on heart failure. Direct overlap with Longeveron's HLHS and PDCM cardiac programs.

Broad incumbents

• Vericel Corporation: Commercial-stage cell therapy company with FDA-approved autologous products (MACI, Epicel). Larger and more established than Longeveron; serves as a benchmark for cell therapy commercialization economics, though focused on autologous rather than allogeneic model.

Emerging players

• Cytori Therapeutics: Developer of adipose-derived regenerative cell therapies (ECCS-50/Celution) for scleroderma, osteoarthritis, and other indications. Comparable regenerative cell therapy approach though focused on adipose rather than bone marrow MSC source.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/longeveron-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds12 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Longeveron